腹腔镜解剖性肝切除术逐步开展治疗肝细胞癌的围手术期与肿瘤学结局
BACKGROUND: Anatomical hepatectomy is an ideal curative treatment for hepatocellular carcinoma (HCC). We have standardized our laparoscopic anatomical hepatectomy (LAH) procedure, gradually extending its indications.…
要点
- 腹腔镜与开腹解剖性肝切除术的重大并发症(12.5% vs 20%)和死亡率(0% vs 3.3%)无显著差异。
- 两组1、3、5年总生存率(腹腔镜89.9%、84.7%、70.9% vs 开腹89.8%、68.0%、63.1%)无显著差异。
- 逐步扩大腹腔镜解剖性肝切除术适应证可获得与开腹手术相当的肿瘤学结局。
核心结论
- 逐步开展腹腔镜解剖性肝切除术治疗原发性肝细胞癌可获得与开腹解剖性肝切除术相当的围手术期和肿瘤学结局。
- 腹腔镜解剖性肝切除术可作为原发性肝细胞癌可行的手术治疗方式,肿瘤学结局良好。
研究设计与样本
- 随腹腔镜经验积累逐步扩大腹腔镜适应证,最终40例行腹腔镜解剖性肝切除术,30例行开腹解剖性肝切除术。
- 比较两组围手术期与肿瘤学结局。
主要发现
- 两组年龄、性别、肝病背景、肝功能、肿瘤大小、肿瘤数目及肝切除类型无显著差异。
- 腹腔镜组与开腹组重大并发症发生率分别为12.5%与20%(p=0.582),死亡率分别为0%与3.3%(p=0.429)。
- 腹腔镜组与开腹组中位随访时间分别为40.5个月与32.9个月(p=0.835)。
- 腹腔镜组1、3、5年总生存率分别为89.9%、84.7%、70.9%,开腹组分别为89.8%、68.0%、63.1%(p=0.255)。
- 腹腔镜组1、3、5年无病生存率分别为79.5%、58.0%、42.5%,开腹组分别为72.4%、56.1%、50.4%(p=0.980)。
临床怎么用
- 在逐步积累腹腔镜经验的前提下,可逐步扩大腹腔镜解剖性肝切除术用于原发性肝细胞癌的适应证。
- 腹腔镜解剖性肝切除术的围手术期安全性和肿瘤学结局与开腹手术相当,可作为可选术式。
局限性
- 单中心回顾性研究,样本量有限(共70例),证据等级受限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Anatomical hepatectomy is an ideal curative treatment for hepatocellular carcinoma (HCC). We have standardized our laparoscopic anatomical hepatectomy (LAH) procedure, gradually extending its indications. In the present study, we describe our experience and the perioperative and oncological outcomes of LAH for HCC compared to those of open anatomical hepatectomy (OAH) during the gradual introduction of LAH. METHODS: Seventy patients with primary HCC underwent anatomical hepatectomy in our institution from November 2008 to April 2014. As we gained experience with LAH, our indications for choosing LAH over OAH gradually expanded. Ultimately, 40 and 30 patients underwent LAH and OAH, respectively. Perioperative and oncological outcomes were compared between the two groups. RESULTS: There were no significant differences in age, sex, background of liver disease, liver function, tumor size, tumor number, or type of liver resection between the two groups. Major complications and mortality rates were similar between the LAH and OAH groups (12.5% vs. 20%; p = 0.582, and 0% vs. 3.3%; p = 0.429, respectively). The median follow-up time after surgery was 40.5 months in the LAH group and 32.9 months in the OAH group (p = 0.835). The 1-, 3-, and 5-year overall survival rates were 89.9, 84.7, and 70.9%, in the LAH group, and 89.8, 68.0, and 63.1% in the OAH group, respectively (p = 0.255). The 1-, 3-, and 5-year disease-free survival rates were 79.5, 58.0, and 42.5%, in the LAH group, and 72.4, 56.1, and 50.4% in the OAH group, respectively (p = 0.980). CONCLUSIONS: Through gradual introduction of LAH, we obtained comparable results to those achieved with OAH. LAH can be a feasible surgical treatment for primary HCC, with good oncological outcomes.
引用
- Ryu T, Honda G, Kurata M, et al. Perioperative and oncological outcomes of laparoscopic anatomical hepatectomy for hepatocellular carcinoma introduced gradually in a single center. Surg Endosc. 2017. PMID: 28733745. doi:10.1007/s00464-017-5745-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。